Daclizumab trial for relapsing-remitting MS begins
Posted: Mon May 24, 2010 5:25 am
Active Comparator Study Designed to Examine the Safety and Efficacy of Daclizumab Formulated for Monthly Subcutaneous Dosing.
Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to to interferon beta-1a (Avonex(R)) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).. [Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1502]